Chinese biotech giant Wuxi AppTec sees first-half earnings surge amid US scrutiny

Wuxi AppTec, Asia’s largest provider of contract pharmaceutical research, posted net income that smashed market expectations in the first half of the year amid strong demand tied to weight-loss and diabetes drugs, as well as gains in its US business. Interim net profit attributable to the owners of the Shanghai-based d

Senior supplies the defence, aerospace and energy sectors with high-tech components and systems.

Eterna Plc reports a significant N5.88bn half-year profit for H1 2026, driven by robust revenue growth and improved operational efficiency across its busin